Approximately $14$ million Americans are addicted to drugs and alcohol. The federal government estimates that these addicts cost the U$.$S$.$ economy $$300$ billion in medical expenses and lost productivity. Despite the enormous potential market, many biotech companies have shied away from funding research and development $($R&D$)$ initiatives to find a cure for drug and alcohol addiction. Your firm Drug Abuse Sciences $($DAS$)-$ is a notable exception. It has spent $$200$ million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $$60$ million today. Unfortunately, the firm's opportunity cost of funds is $5$ percent and it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold. Expected $($year$-$end$)$ profits from selling the drug are presented in the accompanying table.

$\backslash$table$[[$Year $1,$Year $2,$Year $3,$Year $4,$Year $5,$Year $6,$Year $7,$Year $8,$Year $9],[$$$0,$$$0,$$$0,$$$0,$$$12,300,000,$$$14,100,000,$$$16,500,000,$$$18,300,000,$$$21,300,000$